This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Browne, F.W.A. Articles by King, D.J. Search for Related Content PubMed Articles by Browne, F.W.A. Articles by King, D.J. Social Bookmarking                   What's this?

Serum haloperidol levels and clinical response in chronic, treatment-resistant schizophrenic patients

Holywell Hospital, Antrim, N. Ireland, Purdysburn Hospital, Belfast, N. Ireland

S.J. Cooper

Department of Therapeutics and Pharmacology, Queen's University of Belfast BT9 7BL, Holywell Hospital, Antrim, N. Ireland, Department of Mental Health, Queen's University of Belfast

R. Wilson

Department of Therapeutics and Pharmacology, Queen's University of Belfast BT9 7BL

D.J. King

Department of Therapeutics and Pharmacology, Queen's University of Belfast BT9 7BL, Holywell Hospital, Antrim, N. Ireland

Eleven chronic treatment-resistant schizophrenic in-patients were treated with haloperidol (HPL) or placebo with a fixed ascending dose schedule for 20 weeks. Seven patients relapsed and were withdrawn and five of these re-entered, single-blind, on known active treatment. Two weekly clinical ratings and weekly serum HPL levels were carried out throughout the study. More patients on placebo dropped out and at an earlier stage than those on active treatment but the difference was not statistically significant. Despite wide individual variations in both serum HPL levels and clinical response, these were positively correlated. HPL appeared to be of more value in the prevention of relapse than in symptom reduction. Overall, the clinical response was poor and a 'therapeutic window' could not be demonstrated either for the group as a whole or in any individual patient. There was no additional therapeutic benefit in exceeding serum HPL levels of 20 ng/ml in any of our patients. Since this serum level was achieved by daily doses of 10-40 mg HPL and the relationship between dose and serum level is linear, the use of serum HPL estimations is not likely to be of value in the routine clinical management of treatment-resistant patients.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D.J. King, N. Devaney, S.J. Cooper, M. Blomqvist, and M.J. Mitchell Pharmacokinetics and antipsychotic effect of remoxipride in chronic schizophrenic patients J Psychopharmacol, January 1, 1990; 4(2): 83 - 89. [Abstract] [PDF]